JANUARY 7, 2022 by Ken Kingery, Duke University David Needham working on new formulations for niclosamide that could help prevent COVID-19 treatments according to early-stage benchtop studies. Credit: David Needham, Duke University Mechanical engineering and materials science professor David Needham has shown that a slight increase in solution pH might be all it takes to turn...
by Mike Addelman, University of Manchester Credit: Unsplash/CC0 Public Domain The first results of an early trial of a multivariant COVID-19 vaccine booster, launched in Manchester in September 2021, has shown it is driving a comprehensive immune response. U.S.-based biotechnology company Gritstone bio, Inc. in collaboration with The University of Manchester and Manchester University NHS Foundation...
BYHEATHER NEWGEN FACT CHECKED BY ALEK KORAB Shutterstock With Omicron now the dominant COVID-19 variant, doctors are revealing symptoms they’re commonly seeing. Many say the symptoms are close to those of a cold or flu, but according to one well-known New York City emergency physician the severity of Omicron depends on your vaccination status. Read below to see what...
During the first year of the COVID-19 pandemic, emergency use authorizations (EUAs) from the U.S. Food and Drug Administration of COVID-19-related medical products were for diagnostic products and were supported by comparisons to previously authorized assays, according to a research letter published online Dec. 20 in JAMA Internal Medicine. Noting that EUA was used extensively for...
CEDARS-SINAI MEDICAL CENTER LOS ANGELES—Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery—even among people who had mild symptoms or no symptoms at all, according to Cedars-Sinai investigators. The findings are published in the Journal of Translational Medicine. When people are infected with a virus or other...
by Mayo Clinic Credit: Pixabay/CC0 Public Domain For the second time in as many days, the Food and Drug Administration (FDA) has granted emergency use authorization for an investigational antiviral pill to treat COVID-19. This time it is Merck’s molnupiravir. According to the company, under the emergency use authorization, the treatment is cleared to treat mild...
by University of Texas Health Science Center at San Antonio This transmission electron microscope image shows SARS-CoV-2 — also known as 2019-nCoV, the virus that causes COVID-19 — isolated from a patient in the US. Virus particles are shown emerging from the surface of cells cultured in the lab. The spikes on the outer edge...
by University of Zurich Incoming adenovirus particles (AdV) dock at the nuclear pore complexes of a human cell’s nucleus (NPC, dashed line). The cellular enzyme Mind bomb1 (Mib1, grey-white structures) primes them for unlocking and removes protein V (GFP-V, green dots). The uncoated viral DNA genome is then imported into the nucleus. The arrow highlights a...
Shingles is an uncomfortable condition caused by the same virus responsible for chickenpox. The shingles vaccine is a safe and effective tool that can help prevent the condition in eligible adults. The varicella-zoster virus (VZV) is a DNA virus that belongs to the herpesvirus group. After a person recovers from chickenpox, the VZV can remain...
Interview conducted by Emily Henderson, B.Sc. Dec 21, 2021 Thought LeadersProfessor Scott H. FaroProfessor of Radiology and NeurologyThomas Jefferson University In this interview, we speak to Professor Scott H. Faro about his latest research that looked into COVID-19 and its complications within the central nervous system. Please could you introduce yourself, tell us about your...
